• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

精准营养靶向治疗心脏代谢表型的病理生理学。

Precision nutrition for targeting pathophysiology of cardiometabolic phenotypes.

机构信息

Nutrigenomics Research Group, UCD Conway Institute, and Institute of Food and Health, School of Public Health, Physiotherapy and Sports Science, University College Dublin, Dublin, Republic of Ireland.

School of Medicine, University College Dublin, Dublin, Republic of Ireland.

出版信息

Rev Endocr Metab Disord. 2023 Oct;24(5):921-936. doi: 10.1007/s11154-023-09821-5. Epub 2023 Jul 5.

DOI:10.1007/s11154-023-09821-5
PMID:37402955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10492734/
Abstract

Obesity is a heterogenous disease accompanied by a broad spectrum of cardiometabolic risk profiles. Traditional paradigms for dietary weight management do not address biological heterogeneity between individuals and have catastrophically failed to combat the global pandemic of obesity-related diseases. Nutritional strategies that extend beyond basic weight management to instead target patient-specific pathophysiology are warranted. In this narrative review, we provide an overview of the tissue-level pathophysiological processes that drive patient heterogeneity to shape distinct cardiometabolic phenotypes in obesity. Specifically, we discuss how divergent physiology and postprandial phenotypes can reveal key metabolic defects within adipose, liver, or skeletal muscle, as well as the integrative involvement of the gut microbiome and the innate immune system. Finally, we highlight potential precision nutritional approaches to target these pathways and discuss recent translational evidence concerning the efficacy of such tailored dietary interventions for different obesity phenotypes, to optimise cardiometabolic benefits.

摘要

肥胖是一种异质性疾病,伴有广泛的心血管代谢风险谱。传统的饮食体重管理模式没有考虑个体之间的生物学异质性,并且灾难性地未能对抗肥胖相关疾病的全球流行。需要超越基本体重管理的营养策略,转而针对患者特定的病理生理学。在这篇叙述性综述中,我们概述了驱动患者异质性的组织水平病理生理过程,以形成肥胖症中不同的心血管代谢表型。具体来说,我们讨论了不同的生理学和餐后表型如何揭示脂肪、肝脏或骨骼肌内的关键代谢缺陷,以及肠道微生物组和固有免疫系统的综合参与。最后,我们强调了针对这些途径的潜在精准营养方法,并讨论了最近关于这种针对不同肥胖表型的饮食干预的有效性的转化证据,以优化心血管代谢益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38f9/10492734/ac5f7f8b29fe/11154_2023_9821_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38f9/10492734/54a46b9a8774/11154_2023_9821_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38f9/10492734/ac5f7f8b29fe/11154_2023_9821_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38f9/10492734/54a46b9a8774/11154_2023_9821_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38f9/10492734/ac5f7f8b29fe/11154_2023_9821_Fig2_HTML.jpg

相似文献

1
Precision nutrition for targeting pathophysiology of cardiometabolic phenotypes.精准营养靶向治疗心脏代谢表型的病理生理学。
Rev Endocr Metab Disord. 2023 Oct;24(5):921-936. doi: 10.1007/s11154-023-09821-5. Epub 2023 Jul 5.
2
Metabolic phenotyping in people living with obesity: Implications for dietary prevention.肥胖人群的代谢表型:饮食预防的意义。
Rev Endocr Metab Disord. 2023 Oct;24(5):825-838. doi: 10.1007/s11154-023-09830-4. Epub 2023 Aug 15.
3
Dietary macronutrients and the gut microbiome: a precision nutrition approach to improve cardiometabolic health.膳食宏量营养素与肠道微生物组:改善心血管代谢健康的精准营养方法。
Gut. 2022 Jun;71(6):1214-1226. doi: 10.1136/gutjnl-2020-323715. Epub 2022 Feb 8.
4
Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.非酒精性脂肪性肝病与代谢综合征的相互作用。
Obes Rev. 2019 Apr;20(4):599-611. doi: 10.1111/obr.12820. Epub 2018 Dec 27.
5
Current metabolic perspective on malnutrition in obesity: towards more subgroup-based nutritional approaches?当前肥胖相关营养不良的代谢观点:是否应采取更多基于亚组的营养方法?
Proc Nutr Soc. 2020 Aug;79(3):331-337. doi: 10.1017/S0029665120000117. Epub 2020 Mar 3.
6
Perspective: Metabotyping-A Potential Personalized Nutrition Strategy for Precision Prevention of Cardiometabolic Disease.观点:代谢分型——精准预防心血管代谢疾病的个性化营养策略的潜力。
Adv Nutr. 2020 May 1;11(3):524-532. doi: 10.1093/advances/nmz121.
7
Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders.非酒精性脂肪性肝病与心脏代谢紊乱之间的机制联系。
Int J Cardiol. 2015 Dec 15;201:408-14. doi: 10.1016/j.ijcard.2015.08.107. Epub 2015 Aug 10.
8
Feeding the critically ill obese patient: a systematic review protocol.为危重症肥胖患者提供营养支持:一项系统评价方案
JBI Database System Rev Implement Rep. 2015 Oct;13(10):95-109. doi: 10.11124/jbisrir-2015-2458.
9
Precision Nutrition and Cardiovascular Disease Risk Reduction: the Promise of High-Density Lipoproteins.精准营养与心血管疾病风险降低:高密度脂蛋白的前景。
Curr Atheroscler Rep. 2023 Oct;25(10):663-677. doi: 10.1007/s11883-023-01148-5. Epub 2023 Sep 13.
10
Body composition determinants of metabolic phenotypes of obesity in nonobese and obese postmenopausal women.非肥胖和肥胖绝经后妇女肥胖代谢表型的身体成分决定因素。
Obesity (Silver Spring). 2013 Sep;21(9):1807-14. doi: 10.1002/oby.20227. Epub 2013 May 21.

引用本文的文献

1
The source of dietary fat influences anti-tumour immunity in obese mice.膳食脂肪的来源会影响肥胖小鼠的抗肿瘤免疫力。
Nat Metab. 2025 Jul 25. doi: 10.1038/s42255-025-01330-w.
2
Do Precision and Personalised Nutrition Interventions Improve Risk Factors in Adults with Prediabetes or Metabolic Syndrome? A Systematic Review of Randomised Controlled Trials.精准营养和个性化营养干预措施能否改善糖尿病前期或代谢综合征成年人的风险因素?随机对照试验的系统评价。
Nutrients. 2024 May 14;16(10):1479. doi: 10.3390/nu16101479.
3
Phenotyping the obesities: reality or utopia?

本文引用的文献

1
Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease: The TREATY-FLD Randomized Clinical Trial.限时进食对非酒精性脂肪肝的影响:TREATY-FLD 随机临床试验。
JAMA Netw Open. 2023 Mar 1;6(3):e233513. doi: 10.1001/jamanetworkopen.2023.3513.
2
Contemporary medical, device, and surgical therapies for obesity in adults.成人肥胖的当代医学、器械及手术治疗方法。
Lancet. 2023 Apr 1;401(10382):1116-1130. doi: 10.1016/S0140-6736(22)02403-5. Epub 2023 Feb 9.
3
Butyrate and hexanoate-enriched triglycerides increase postprandrial systemic butyrate and hexanoate in men with overweight/obesity: A double-blind placebo-controlled randomized crossover trial.
肥胖表型化:现实还是乌托邦?
Rev Endocr Metab Disord. 2023 Oct;24(5):767-773. doi: 10.1007/s11154-023-09829-x. Epub 2023 Aug 4.
富含丁酸酯和己酸酯的甘油三酯可增加超重/肥胖男性餐后的全身丁酸酯和己酸酯水平:一项双盲安慰剂对照随机交叉试验。
Front Nutr. 2023 Jan 4;9:1066950. doi: 10.3389/fnut.2022.1066950. eCollection 2022.
4
Cardiometabolic health improvements upon dietary intervention are driven by tissue-specific insulin resistance phenotype: A precision nutrition trial.饮食干预对心脏代谢健康的改善是由组织特异性胰岛素抵抗表型驱动的:一项精准营养试验。
Cell Metab. 2023 Jan 3;35(1):71-83.e5. doi: 10.1016/j.cmet.2022.12.002.
5
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.超重和肥胖人群中非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球患病率:一项系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2023 Jan;8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X. Epub 2022 Nov 16.
6
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.LY3437943,一种新型三重 GIP、GLP-1 和胰高血糖素受体激动剂,用于 2 型糖尿病患者:一项 1b 期、多中心、双盲、安慰剂对照、随机、多次递增剂量试验。
Lancet. 2022 Nov 26;400(10366):1869-1881. doi: 10.1016/S0140-6736(22)02033-5. Epub 2022 Oct 27.
7
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.超重或肥胖成年人中司美格鲁肽的 2 年疗效:STEP 5 试验。
Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10.
8
High-fructose feeding suppresses cold-stimulated brown adipose tissue glucose uptake independently of changes in thermogenesis and the gut microbiome.高果糖喂养可抑制冷刺激棕色脂肪组织对葡萄糖的摄取,而不影响产热和肠道微生物组的变化。
Cell Rep Med. 2022 Sep 20;3(9):100742. doi: 10.1016/j.xcrm.2022.100742.
9
Total Postprandial Hepatic Nonesterified and Dietary Fatty Acid Uptake Is Increased and Insufficiently Curbed by Adipose Tissue Fatty Acid Trapping in Prediabetes With Overweight.超重的糖尿病前期患者,其脂肪组织脂肪酸截留导致餐后肝脏非酯化和膳食脂肪酸摄取增加,且不能充分抑制。
Diabetes. 2022 Sep 1;71(9):1891-1901. doi: 10.2337/db21-1097.
10
Tirzepatide Once Weekly for the Treatment of Obesity.司美格鲁肽每周一次治疗肥胖症。
N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.